EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Inter-Atrial Block as a Predictor of Adverse Outcomes in Patients with HFpEF

Jerremy Weerts, Sanne G J Mourmans iD, Helena Lopez-Martinez, Mar Domingo, Arantxa Barandiarán Aizpurua, Michiel T H M Henkens, Anouk Achten, Josep Lupón, Hans-Peter Brunner-La Rocca, Christian Knackstedt, Antoni Bayés-Genís, Vanessa P M van Empel

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15179 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Jerremy Weerts und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre+ (MUMC+), Maastricht, The Nether…. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Interatrial Block, Heart Atria. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dutch Heart Foundation, Health Foundation Limburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Inter-atrial block (IAB), a marker of electrical atrial dysfunction, is associated with an increased risk of atrial fibrillation (AF) and adverse events in various populations. The prognostic impact of IAB in heart failure (HF) with preserved ejection fraction (HFpEF) remains unknown. The aim of this study is to determine the prevalence of IAB and the association of IAB and AF with adverse events in HFpEF across different healthcare settings. Methods and results To identify electrical atrial dysfunction, baseline ECG's and medical history were analysed in HFpEF patients in an ambulatory setting and after recent HF hospitalisation. Patients were categorised into (i) HFpEFNo IAB, (ii) HFpEFIAB, or (iii) HFpEFAF. Adverse events included HF hospitalisation, cardiac/sudden death and a composite of both. The ambulatory cohort included 372 patients [mean age 75 ± 7 years, 252 (68%) females]. The recently hospitalised cohort included 132 patients [mean age 81 ± 10 years, 80 (61%) females]. Ambulatory patients included 17 (4%) HFpEFnoIAB, 114 (31%) HFpEFIAB and 241 (65%) HFpEFAF, while recently hospitalised patients included 31 (23%), 73 (55%) and 28 (21%), respectively. After 33 months of follow-up of ambulatory patients, composite endpoints occurred in 0 (0%) HFpEFnoIAB, 12 (11%) HFpEFIAB [HR 4.1 (95% CI 0.5–522.6)] and 59 (24%) HFpEFAF patients [HR 10.1 (95% CI 1.5–1270.4), P < 0.001]. Recently hospitalised patients showed a similar trend, with composite endpoints in 10 (32%) HFpEFnoIAB, 31 (42%) HFpEFIAB (HR 1.5 [95% CI 0.7–3.1]) and 22 (79%) HFpEFAF (HR 3.8 [95% CI 1.8–8.1], P < 0.001).

Conclusions

Progressive stages of electrical atrial dysfunction appeared to be prognostic markers of adverse outcomes in ambulatory and recently hospitalised patients with HFpEF. Ambulatory patients with HFpEF and no early stages of electrical atrial dysfunction showed to be at very low risk for adverse outcomes. Whether such patients benefit less strict management remains to be investigated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeInteratrial BlockHeart AtriaHumansFemaleMaleAgedPrognosisAged, 80 and overElectrocardiographyFollow-Up StudiesHospitalizationRetrospective StudiesAtrial FibrillationRisk Factors

Stichwörter der Autor:innen

Atrial dysfunctionAtrial fibrillationElectrocardiographyHeart atriaHeart failure with preserved ejection fractionPrognosis

Autor:innen und Institutionen

  • Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre+ (MUMC+), Maastricht, The Netherlands.
  • Heart Institute, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
  • Department of Pathology, Maastricht University Medical Centre+ (MUMC+), Maastricht, The Netherlands.
  • Netherlands Heart Institute (NLHI), Utrecht, The Netherlands.
  • CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.

ORCID-Profile: Sanne G J Mourmans

Förderung

  • Dutch Heart Foundation
  • Health Foundation Limburg

Zitieren

APA

Weerts, J., Mourmans, S. G. J., Lopez-Martinez, H., Domingo, M., Aizpurua, A. B., Henkens, M. T. H. M., Achten, A., Lupón, J., Rocca, H. B., Knackstedt, C., Bayés-Genís, A., & van Empel, V. P. M. (2025). Inter-Atrial Block as a Predictor of Adverse Outcomes in Patients with HFpEF. ESC Heart Failure. https://doi.org/10.1002/ehf2.15179

Vancouver

Weerts J, Mourmans SGJ, Lopez-Martinez H, Domingo M, Aizpurua AB, Henkens MTHM, et al. Inter-Atrial Block as a Predictor of Adverse Outcomes in Patients with HFpEF. ESC Heart Failure. 2025. doi:10.1002/ehf2.15179

BibTeX
@article{Weerts2025,
  author = {Weerts, Jerremy and Mourmans, Sanne G J and Lopez-Martinez, Helena and Domingo, Mar and Aizpurua, Arantxa Barandiarán and Henkens, Michiel T H M and Achten, Anouk and Lupón, Josep and Rocca, Hans-Peter Brunner-La and Knackstedt, Christian and Bayés-Genís, Antoni and van Empel, Vanessa P M},
  title = {Inter-Atrial Block as a Predictor of Adverse Outcomes in Patients with HFpEF},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15179}
}
Kostenlos starten →